» Articles » PMID: 6256319

Phase I-II Study of Radiolabeled Antibody Integrated in the Treatment of Primary Hepatic Malignancies

Overview
Specialties Oncology
Radiology
Date 1980 Jun 1
PMID 6256319
Citations 15
Authors
Affiliations
Soon will be listed here.
Citing Articles

Cellular Response to Exponentially Increasing and Decreasing Dose Rates: Implications for Treatment Planning in Targeted Radionuclide Therapy.

Solanki J, Tritt T, Pasternack J, Kim J, Leung C, Domogauer J Radiat Res. 2017; 188(2):221-234.

PMID: 28541775 PMC: 5669265. DOI: 10.1667/RR14766.1.


Cancer radioimmunotherapy.

Sharkey R, Goldenberg D Immunotherapy. 2011; 3(3):349-70.

PMID: 21395378 PMC: 3123828. DOI: 10.2217/imt.10.114.


Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.

Sharkey R, Rossi E, McBride W, Chang C, Goldenberg D Semin Nucl Med. 2010; 40(3):190-203.

PMID: 20350628 PMC: 2855818. DOI: 10.1053/j.semnuclmed.2009.12.002.


Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.

Howell R, Goddu S, Rao D Med Phys. 1998; 25(1):37-42.

PMID: 9472824 PMC: 3046635. DOI: 10.1118/1.598171.


Radioimmunotechnology for cancer diagnosis and treatment.

Holt S, Longenecker B, Noujaim A Can Med Assoc J. 1983; 129(1):18-9, 41.

PMID: 6861042 PMC: 1874925.